Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index.
Abstract
The purpose of this study was to use serial imaging to gain insight into the sequence of pathologic events in Alzheimer's disease, and the clinical features associated with this sequence. We measured change in amyloid deposition over time using serial (11)C Pittsburgh compound B (PIB) positron emission tomography and progression of neurodegeneration using serial structural magnetic resonance imaging. We studied 21 healthy cognitively normal subjects, 32 with amnestic mild cognitive impairment and 8 with Alzheimer's disease. Subjects were drawn from two sources--ongoing longitudinal registries at Mayo Clinic, and the Alzheimer's disease Neuroimaging Initiative (ADNI). All subjects underwent clinical assessments, MRI and PIB studies at two time points, approximately one year apart. PIB retention was quantified in global cortical to cerebellar ratio units and brain atrophy in units of cm(3) by measuring ventricular expansion. The annual change in global PIB retention did not differ by clinical group (P = 0.90), and although small (median 0.042 ratio units/year overall) was greater than zero among all subjects (P < 0.001). Ventricular expansion rates differed by clinical group (P < 0.001) and increased in the following order: cognitively normal (1.3 cm(3)/year) < amnestic mild cognitive impairment (2.5 cm(3)/year) < Alzheimer's disease (7.7 cm(3)/year). Among all subjects there was no correlation between PIB change and concurrent change on CDR-SB (r = -0.01, P = 0.97) but some evidence of a weak correlation with MMSE (r =-0.22, P = 0.09). In contrast, greater rates of ventricular expansion were clearly correlated with worsening concurrent change on CDR-SB (r = 0.42, P < 0.01) and MMSE (r =-0.52, P < 0.01). Our data are consistent with a model of typical late onset Alzheimer's disease that has two main features: (i) dissociation between the rate of amyloid deposition and the rate of neurodegeneration late in life, with amyloid deposition proceeding at a constant slow rate while neurodegeneration accelerates and (ii) clinical symptoms are coupled to neurodegeneration not amyloid deposition. Significant plaque deposition occurs prior to clinical decline. The presence of brain amyloidosis alone is not sufficient to produce cognitive decline, rather, the neurodegenerative component of Alzheimer's disease pathology is the direct substrate of cognitive impairment and the rate of cognitive decline is driven by the rate of neurodegeneration. Neurodegeneration (atrophy on MRI) both precedes and parallels cognitive decline. This model implies a complimentary role for MRI and PIB imaging in Alzheimer's disease, with each reflecting one of the major pathologies, amyloid dysmetabolism and neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Efforts continue to be placed on the early detection of AD as changes in brain chemistry begin to occur 20 years or more prior to the onset of noticeable cognitive symptoms [137,138,139,140].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [137]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although these symptoms are new to the individual affected, the brain changes that cause them are thought to begin 20 years or more before symptoms start.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Studies of non-demented elderly cohorts overall report approximately 20–40% are PIB-positive [67, 68, 71–78].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., & Joliot, M. (2002) · NeuroImage · doi:10.1006/nimg.2001.0978 · Cited by 16,319 · cited 1×
“The automated anatomic labelling (AAL) atlas (Tzourio-Mazoyer et al., 2002) was modified in-house to contain the following labelled regions of interest: right and left parietal, temporal, prefrontal, primary sensory -motor, orbito frontal, anterior cingulate, posterior cingulate/ precuneus and occipital.”
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Hu, R. J. (2003) · Encyclopedia of the Neurological Sciences · doi:10.1016/b0-12-226870-9/01070-4 · Cited by 9,117
Diagnostic and Statistical Manual of Mental Disorders
Siegel, L. J., & Fletcher‐Janzem, E. (2008) · Encyclopedia of Special Education · doi:10.1002/9780470373699.speced0655 · Cited by 8,477
What's wrong with Bonferroni adjustments
Perneger, T. V. (1998) · BMJ · doi:10.1136/bmj.316.7139.1236 · Cited by 5,900
Current concepts in mild cognitive impairment
Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.1985 · Cited by 4,781
Self-citation
Cited by
Items 301–400 of 1,000
Sierks, M. R., Chatterjee, G., McGraw, C., Kasturirangan, S., Schulz, P., & Prasad, S. (2011) · Integrative Biology · doi:10.1039/c1ib00018g · Cited by 84
López, O. L. (2013) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000429175.29601.97 · Cited by 108
Effects of education on aging-related cortical thinning among cognitively normal individuals
Kim, J. P., Seo, S. W., Shin, H. Y., Ye, B. S., Yang, J.-J., Kim, C., Kang, M., Jeon, S., Kim, H. J., Cho, H., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001884 · Cited by 80
Maarouf, C. L., Daugs, I. D., Kokjohn, T. A., Walker, D. G., Hunter, J. M., Kruchowsky, J. C., Woltjer, R., Kaye, J., Castaño, E. M., Sabbagh, M. N., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027291 · Cited by 80
Nonlinear time course of brain volume loss in cognitively normal and impaired elders
Schuff, N., Tosun, D., Insel, P. S., Chiang, G. C., Truran, D., Aisen, P. S., Jack, C. R., & Weiner, M. W. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.07.012 · Cited by 82
Self-citationAssociation of hypometabolism and amyloid levels in aging, normal subjects
Lowe, V. J., Weigand, S. D., Senjem, M. L., Vemuri, P., Jordan, L., Kantarci, K., Boeve, B., Jack, C. R., Knopman, D., & Petersen, R. C. (2014) · Neurology · doi:10.1212/wnl.0000000000000467 · Cited by 80
Self-citationAlves, C. L., Pineda, A. M., Roster, K. I. O., Thielemann, C., & Rodrigues, F. A. (2022) · Journal of Physics Complexity · doi:10.1088/2632-072x/ac5f8d · Cited by 102
Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment
Schott, J. M., Bartlett, J. W., Barnes, J., Leung, K. K., Ourselin, S., & Fox, N. C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.011 · Cited by 77
Change in plasma Aβ peptides and onset of dementia in adults with Down syndrome
Schupf, N., Zigman, W. B., Tang, M.-X., Pang, D., Mayeux, R., Mehta, P., & Silverman, W. (2010) · Neurology · doi:10.1212/wnl.0b013e3181fb448b · Cited by 79
Alzheimer’s disease biomarkers and their current use in clinical research and practice
Hunter, T., Santos, L. E., Tovar-Moll, F. F., & Felice, F. G. D. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02709-z · Cited by 88
Sabbagh, J. J., Kinney, J. W., & Cummings, J. L. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.02.027 · Cited by 84
Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease
Ng, K. P., Pascoal, T. A., Mathotaarachchi, S., Chung, C.-O., Benedet, A. L., Shin, M., Kang, M. S., Li, X., Ba, M., Kandiah, N., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003916 · Cited by 74
Self-citationMaternal family history is associated with Alzheimer's disease biomarkers
Honea, R. A., Initiative, F. T. A. D. N., Vidoni, E. D., Swerdlow, R. H., & Burns, J. M. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120676 · Cited by 79
SantaCruz, K. S., Sonnen, J. A., Pezhouh, M. K., Desrosiers, M. F., Nelson, P. T., & Tyas, S. L. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31822e8ae9 · Cited by 79
Laforce, R., & Rabinovici, G. D. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt93 · Cited by 79
Okonkwo, O. C. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.118 · Cited by 75
Changes in regional brain volume three months after stroke
Brodtmann, A. G., Pardoe, H., Li, Q., Lichter, R., Østergaard, L., & Cumming, T. B. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.07.019 · Cited by 77
Presymptomatic spinal cord neurometabolic findings inSOD1-positive people at risk for familial ALS
Carew, J. D., Nair, G., Andersen, P. M., Wuu, J., Gronka, S., Hu, X. P., & Benatar, M. G. (2011) · Neurology · doi:10.1212/wnl.0b013e318231526a · Cited by 81
Cerebral Serotonin 4 Receptors and Amyloid-β in Early Alzheimer's Disease
Madsen, K., Neumann, W.-J., Holst, K., Marner, L., Haahr, M. T., Lehel, S., Knudsen, G. M., & Hasselbalch, S. G. (2011) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2011-110056 · Cited by 72
Distribution of Pathology in Frontal Variant Alzheimer's Disease
Blennerhassett, R., Lillo, P., Halliday, G. M., Hodges, J. R., & Kril, J. J. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-131241 · Cited by 71
Galluzzi, S., Marizzoni, M., Babiloni, C., Albani, D., Antelmi, L., Bagnoli, C., Bartres‐Faz, D., Cordone, S., Didic, M., Farotti, L., et al. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12482 · Cited by 76
Webster, L., Groskreutz, D., Grinbergs-Saull, A., Howard, R., O’Brien, J. T., Mountain, G., Banerjee, S., Woods, B., Perneczky, R., Lafortune, L., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21260 · Cited by 74
Presenilin-1 adopts pathogenic conformation in normal aging and in sporadic Alzheimer’s disease
Wahlster, L., Arimon, M., Nasser-Ghodsi, N., Post, K. L., Serrano-Pozo, A., Uemura, K., & Berezovska, O. (2013) · Acta Neuropathologica · doi:10.1007/s00401-012-1065-6 · Cited by 71
Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration
Höglund, K., Kern, S., Zettergren, A., Börjesson-Hansson, A., Zetterberg, H., Skoog, I., & Blennow, K. (2017) · Translational Psychiatry · doi:10.1038/tp.2016.252 · Cited by 74
Imaging and Molecular Mechanisms of Alzheimer’s Disease: A Review
Femminella, G. D., Thayanandan, T., Calsolaro, V., Komici, K., Rengo, G., Corbi, G., & Ferrara, N. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123702 · Cited by 79
Jones-Odeh, E., & Hammond, C. J. (2015) · Eye · doi:10.1038/eye.2015.158 · Cited by 80
Amyloid PET imaging: applications beyond Alzheimer’s disease
Catafau, A. M., & Bullich, S. (2015) · Clinical and Translational Imaging · doi:10.1007/s40336-014-0098-3 · Cited by 71
Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer’s aetiopathology
Okada, H., Ouchi, Y., Ogawa, M., Futatsubashi, M., Saito, Y., Yoshikawa, E., Terada, T., Oboshi, Y., Tsukada, H., Ueki, T., et al. (2013) · Brain · doi:10.1093/brain/awt195 · Cited by 71
Apolipoprotein E gene polymorphism and Alzheimer's disease in Chinese population: a meta-analysis
Liu, M., Bian, C., Zhang, J., & Wen, F. (2014) · Scientific Reports · doi:10.1038/srep04383 · Cited by 72
Dief, A. E., Kamha, E. S., Baraka, A., & Elshorbagy, A. K. (2014) · NeuroToxicology · doi:10.1016/j.neuro.2014.04.003 · Cited by 76
Preclinical AD Workgroup staging: Pathological correlates and potential challenges
Jicha, G. A., Abner, E. L., Schmitt, F. A., Kryscio, R. J., Riley, K. P., Cooper, G. E., Stiles, N., Mendiondo, M. S., Smith, C. D., Van Eldik, L. J., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.02.018 · Cited by 71
“…2005; Davatzikos et al., 2010; de Leon et al., 2007; Dubois et al., 2007; Engelborghs et al., 2007; Fagan et al., 2007; Haense et al., 2009; Jack et al., 2009, 2010a; Jagust et al., 2010; Johnson et al., 1998; Kapaki et al., 2003; Li et al., 2008; Mintun et al., 2006; Misra et al., 2009;…”
Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer’s disease
Cody, K. A., Langhough, R. E., Zammit, M. D., Clark, L. R., Chin, N. A., Christian, B. T., Betthauser, T. J., & Johnson, S. C. (2024) · Brain · doi:10.1093/brain/awae116 · Cited by 73
Zhang, B., Xu, Y., Zhu, B., & Kantarci, K. (2014) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12166 · Cited by 68
Antibody‐Mimetic Peptoid Nanosheet for Label‐Free Serum‐Based Diagnosis of Alzheimer's Disease
Zhu, L., Zhao, Z., Cheng, P., He, Z., Cheng, Z., Peng, J., Wang, H., Wang, C., Yang, Y., & Hu, Z. (2017) · Advanced Materials · doi:10.1002/adma.201700057 · Cited by 71
Kawasaki, R., Cheung, N., Mosley, T. H., Islam, A. F. M., Sharrett, A. R., Klein, R., Coker, L. H., Knopman, D. S., Shibata, D. K., Catellier, D., et al. (2010) · Stroke · doi:10.1161/strokeaha.110.585042 · Cited by 70
Self-citationThe Down syndrome brain in the presence and absence of fibrillar β-amyloidosis
Annus, T., Wilson, L. R., Acosta-Cabronero, J., Cardenas-Blanco, A., Hong, Y. T., Fryer, T. D., Coles, J. P., Menon, D. K., Zaman, S. H., Holland, A. J., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.01.009 · Cited by 65
Positron emission tomography radioligands for in vivo imaging of Aβ plaques
Mason, N. S., Mathis, C. A., & Klunk, W. E. (2013) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.2989 · Cited by 71
Mosconi, L., Rinne, J. O., Tsui, W. H., Murray, J., Li, Y., Glodzik, L., McHugh, P., Williams, S., Cummings, M., Pirraglia, E., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.03.002 · Cited by 67
Gray matter networks and clinical progression in subjects with predementia Alzheimer's disease
Tijms, B. M., ten Kate, M., Gouw, A. A., Borta, A., Verfaillie, S. C. J., Teunissen, C. E., Scheltens, P., Barkhof, F., & van der Flier, W. M. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.09.011 · Cited by 70
Initiative, F. T. A. D. N., Caldwell, J. Z. K., Berg, J.-L., Cummings, J. L., & Banks, S. J. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0300-8 · Cited by 65
Pathobiological Subtypes of Alzheimer Disease
Jellinger, K. A. (2020) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000508625 · Cited by 67
Knopman, D. S., Jack, C. R., Wiste, H. J., Weigand, S. D., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Mielke, M. M., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.182 · Cited by 68
Self-citationMüller cell degeneration and microglial dysfunction in the Alzheimer’s retina
Xu, Q., Boerkoel, P., Hirsch‐Reinshagen, V., Mackenzie, I. R., Hsiung, G. R., Charm, G., To, E., Liu, A., Schwab, K. D., Jiang, K., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01448-y · Cited by 68
Metabolomic epidemiology offers insights into disease aetiology
Fuller, H., Zhu, Y., Nicholas, J. C., Chatelaine, H., Drzymalla, E., Sarvestani, A. K., Julián‐Serrano, S., Tahir, U. A., Sinnott-Armstrong, N., Raffield, L. M., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00903-x · Cited by 69
18F-florbetaben Aβ imaging in mild cognitive impairment
Ong, K., Villemagne, V. L., Bahar-Fuchs, A., Lamb, F., Chételat, G., Raniga, P., Mulligan, R. S., Salvado, O., Putz, B., Roth, K., et al. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt158 · Cited by 64
Ralbovsky, N. M., Halámková, L., Wall, K. M., Anderson‐Hanley, C., & Lednev, I. K. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190675 · Cited by 74
(ADNI), F. T. A. D. N. I., Ramanan, V. K., Kim, S., Holohan, K., Shen, L., Nho, K., Risacher, S. L., Foroud, T. M., Mukherjee, S., Crane, P. K., et al. (2012) · Brain Imaging and Behavior · doi:10.1007/s11682-012-9196-x · Cited by 67
Self-citationLack of association between prior depressive episodes and cerebral [11C]PiB binding
Madsen, K., Hasselbalch, B. J., Frederiksen, K. S., Haahr, M. E., Gade, A., Law, I., Price, J. C., Knudsen, G. M., Kessing, L. V., & Hasselbalch, S. G. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.11.021 · Cited by 66
Zhang, S., Smailagic, N., Hyde, C., Noel-Storr, A. H., Takwoingi, Y., McShane, R., & Feng, J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010386.pub2 · Cited by 66
Landt, J. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.36 · Cited by 65
Julkunen, V., Niskanen, E., Muehlboeck, S., Pihlajamäki, M., Könönen, M., Hallikainen, M., Kivipelto, M., Tervo, S., Vanninen, R., Evans, A., et al. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000256274 · Cited by 59
Ventricular maps in 804 ADNI subjects: correlations with CSF biomarkers and clinical decline
Chou, Y.-Y., Leporé, N., Saharan, P., Madsen, S. K., Hua, X., Jack, C. R., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W., Toga, A. W., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.001 · Cited by 65
Self-citationSarraf, S., DeSouza, D. D., Anderson, J. A. E., & Saverino, C. (2019) · IEEE Access · doi:10.1109/access.2019.2949577 · Cited by 78
Update on amyloid imaging: From healthy aging to Alzheimer’s disease
Wolk, D. A., & Klunk, W. E. (2009) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-009-0051-4 · Cited by 63
Secondary prevention of Alzheimer’s dementia: neuroimaging contributions
ten Kate, M., Ingala, S., Schwarz, A. J., Fox, N. C., Chételat, G., van Berckel, B. N. M., Ewers, M., Foley, C., Gispert, J. D., Hill, D., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0438-z · Cited by 70
Alliance for aging research AD biomarkers work group: structural MRI
Jack, C. R. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.011 · Cited by 64
“This amyloid and neurodegeneration model (Jack et al., 2009) is reproduced in Fig.”
Self-citationKumar, A., Karuppagounder, S. S., Chen, Y., Corona, C., Kawaguchi, R., Cheng, Y., Balkaya, M., Sagdullaev, B. T., Wen, Z., Stuart, C., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.06.013 · Cited by 64
Amyloid and Alzheimer's Disease: Inside and Out
Tam, J. H. K., & Pasternak, S. H. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100013408 · Cited by 66
The AppNL-G-F mouse retina is a site for preclinical Alzheimer’s disease diagnosis and research
Vandenabeele, M., Veys, L., Lemmens, S., Hadoux, X., Gelders, G., Masin, L., Serneels, L., Theunis, J., Saito, T., Saido, T. C., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01102-5 · Cited by 64
Aβ amyloid, cognition, and APOE genotype in healthy older adults
Lim, Y. Y., Ellis, K. A., Ames, D., Darby, D., Harrington, K., Martins, R. N., Masters, C. L., Rowe, C., Savage, G., Szoeke, C., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.07.004 · Cited by 57
Target-Specific PET Probes for Neurodegenerative Disorders Related to Dementia
Kadir, A., & Nordberg, A. K. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.077164 · Cited by 70
Sreekumar, V., Nielson, D. M., Smith, T. A., Dennis, S. J., & Sederberg, P. B. (2018) · Scientific Reports · doi:10.1038/s41598-018-32879-0 · Cited by 64
Machulda, M. M., Hagen, C. E., Wiste, H. J., Mielke, M. M., Knopman, D. S., Roberts, R. O., Vemuri, P., Lowe, V. J., Jack, C. R., & Petersen, R. C. (2017) · The Clinical Neuropsychologist · doi:10.1080/13854046.2016.1241303 · Cited by 59
Self-citationAmyloid Imaging with PET in Early Alzheimer Disease Diagnosis
Rowe, C. C., & Villemagne, V. L. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.12.017 · Cited by 67
Tarumi, T., de Jong, D. L. K., Zhu, D. C., Tseng, B. Y., Liu, J., Hill, C., Riley, J. R., Womack, K. B., Kerwin, D. R., Lu, H., et al. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.01.041 · Cited by 66
Leijenaar, J. F., van Maurik, I. S., Kuijer, J. P. A., van der Flier, W. M., Scheltens, P., Barkhof, F., & Prins, N. D. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.10.001 · Cited by 59
MRI-based evaluation of structural degeneration in the ageing brain: Pathophysiology and assessment
Grajauskas, L. A., Siu, W. W. Y., Medvedev, G., Guo, H., D’Arcy, R. C. N., & Song, X. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.11.004 · Cited by 66
Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia
Rittman, T., Borchert, R., Jones, S., van Swieten, J., Borroni, B., Galimberti, D., Masellis, M., Tartaglia, M. C., Graff, C., Tagliavini, F., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.12.009 · Cited by 59
Topographical Heterogeneity of Alzheimer’s Disease Based on MR Imaging, Tau PET, and Amyloid PET
Jeon, S., Kang, J. M., Seo, S., Jeong, H. J., Funck, T., Lee, S.-Y., Park, K. H., Lee, Y.-B., Yeon, B. K., Ido, T., et al. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00211 · Cited by 59
Guercio, B. J., Donovan, N. J., Ward, A., Schultz, A., Lorius, N., Amariglio, R. E., Rentz, D. M., Johnson, K. A., Sperling, R. A., & Marshall, G. A. (2015) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/appi.neuropsych.13060141 · Cited by 61
Alzheimer's disease: progress in prediction
Petersen, R. C. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70330-8 · Cited by 60
Self-citationClinical and imaging characteristics of dementia in multiple system atrophy
Kim, H., Jeon, B. S., Kim, Y. E., Kim, J.-Y., Kim, Y. K., Sohn, C., Yun, J. Y., Jeon, S., Lee, J., & Lee, J. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2013.02.012 · Cited by 61
Nestor, S. M., Gibson, E., Gao, F.-Q., Kiss, A., & Black, S. E. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2012.10.081 · Cited by 60
Bangen, K. J., Clark, A. L., Edmonds, E. C., Evangelista, N. D., Werhane, M. L., Thomas, K. R., Locano, L. E., Tran, M., Zlatar, Z. Z., Nation, D. A., et al. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00181 · Cited by 55
Polygenic risk and pleiotropy in neurodegenerative diseases
Bellou, E., Stevenson-Hoare, J., & Escott-Price, V. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104953 · Cited by 50
3D Convolutional Neural Networks for Diagnosis of Alzheimer's Disease via Structural MRI
Yağış, E., Citi, L., Diciotti, S., Marzi, C., Atnafu, S. W., & de Herrera, A. G. S. (2020) · Proceedings - IEEE Symposium on Computer-Based Medical Systems · doi:10.1109/cbms49503.2020.00020 · Cited by 74
A Dietary Treatment Improves Cerebral Blood Flow and Brain Connectivity in Aging apoE4 Mice
Wiesmann, M., Zerbi, V., Jansen, D., Haast, R., Lütjohann, D., Broersen, L. M., Heerschap, A., & Kiliaan, A. J. (2016) · Neural Plasticity · doi:10.1155/2016/6846721 · Cited by 60
Alzheimer’s Disease Neuroimaging Initiative
Bernick, C. B. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108975759.041 · Cited by 60
Reliable Measurements of theβ-Amyloid Pool in Blood Could Help in the Early Diagnosis of AD
Pesini, P., Pérez‐Grijalba, V., Monleón, I., Boada, M., Tárraga, L., Martínez‐Lage, P., José, I. S., & Sarasa, M. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/604141 · Cited by 65
Hatashita, S., & Yamasaki, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066877 · Cited by 57
Nordberg, A. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt96 · Cited by 56
Goveas, J. S., Xie, C., Chen, G., Li, W., Ward, B. D., Franczak, M. B., Jones, J. L., Antuono, P., & Li, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055902 · Cited by 60
New treatment strategies for Alzheimer's disease: is there a hope?
Aprahamian, I., Stella, F., & Forlenza, O. V. (2013) · Europe PMC (PubMed Central) · Cited by 80
Amyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old
Lopez, O. L., Klunk, W. E., Mathis, C., Coleman, R. L., Price, J., Becker, J. T., Aizenstein, H. J., Snitz, B., Cohen, A., Ikonomovic, M., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000977 · Cited by 57
Integrating ADNI results into Alzheimer's disease drug development programs
Cummings, J. L. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.016 · Cited by 59
Hampel, H. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129003 · Cited by 53
Yan, Z., Liao, H., Chen, H., Deng, S., Jia, Y., Deng, C., Lin, J., Ge, J., & Zhuo, Y. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-22312 · Cited by 58
Hu, H., Initiative, A. D. N., Chen, K.-L., Ou, Y.-N., Cao, X.-P., Chen, S.-D., Cui, M., Dong, Q., Tan, L., & Yu, J.-T. (2019) · Aging · doi:10.18632/aging.102220 · Cited by 59
Bubu, O. M., Umasabor‐Bubu, O. Q., Turner, A. D., Parekh, A., Mullins, A. E., Kam, K., Birckbichler, M. K., Mukhtar, F., Mbah, A. K., Williams, N. J., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12184 · Cited by 63
Morinaga, A., Ono, K., Ikeda, T., Ikeda, Y., Shima, K., Noguchi-Shinohara, M., Samuraki, M., Yanase, D., Yoshita, M., Iwasa, K., et al. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000320265 · Cited by 50
Stable Size Distribution of Amyloid Plaques Over the Course of Alzheimer Disease
Serrano-Pozo, A., Mielke, M. L., Muzitansky, A., Gómez-Isla, T., Growdon, J. H., Bacskai, B. J., Betensky, R. A., Frosch, M. P., & Hyman, B. T. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825e77de · Cited by 56
Budd, D., Burns, Guo, L’Italien, & Lapuerta (2011) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s22265 · Cited by 61
Serum Hepcidin Levels, Iron Dyshomeostasis and Cognitive Loss in Alzheimer’s Disease
Sternberg, Z., Hu, Z., Sternberg, D. S., Waseh, S., Quinn, J. F., Wild, K., Kaye, J. A., Zhao, L., & Garrick, M. D. (2017) · Aging and Disease · doi:10.14336/ad.2016.0811 · Cited by 60
The spectrum of preclinical Alzheimer's disease pathology and its modulation by ApoE genotype
Pletnikova, O., Kageyama, Y., Rudow, G., LaClair, K. D., Albert, M., Crain, B. J., Tian, J., Fowler, D., & Troncoso, J. C. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.07.007 · Cited by 58
Humanin and the Receptors for Humanin
Matsuoka, M., & Hashimoto, Y. (2009) · Molecular Neurobiology · doi:10.1007/s12035-009-8090-z · Cited by 60
Imaging and Biomarkers in Early Alzheimer's Disease and Mild Cognitive Impairment
Petersen, R. C., & Jack, C. R. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.166 · Cited by 57
Self-citationShinohara, M., Petersen, R. C., Dickson, D. W., & Bu, G. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1086-9 · Cited by 56
Self-citationNeuroimaging in aging and neurologic diseases
Risacher, S. L., & Saykin, A. J. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804766-8.00012-1 · Cited by 82
Shin, J., Lee, J. K., Lee, J. E., Min, W., Schuchman, E. H., Jin, H. K., & Bae, J. (2011) · STEM CELLS · doi:10.1002/stem.659 · Cited by 57
A Focus on Structural Brain Imaging in the Alzheimer’s Disease Neuroimaging Initiative
Braskie, M. N., & Thompson, P. M. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.11.020 · Cited by 51
Metadata
- Authors
- Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., Weiner, M., & Petersen, R. C.
- Affiliations
- Mayo Clinic (US)
- San Francisco VA Medical Center (US)
- Corresponding author
- Jack, Clifford R.
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-03-31
- Volume
- 132
- Issue
- 5
- Pages
- 1355-1365
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC2677798
- OpenAlex
- W2133719476
- Cited by
- 1,099
- References
- 83
- Citations by year
- 2026: 29 · 2025: 28 · 2024: 34 · 2023: 51 · 2022: 45 · 2021: 49 · 2020: 60 · 2019: 54 · 2018: 62 · 2017: 46 · 2016: 56 · 2015: 69 · 2014: 73 · 2013: 94 · 2012: 116
- FWCI
- 71.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Mayo Foundation for Medical Education and Research (AG16574)
- National Institute for Health and Care Research (NF-SI-0508-10123)
- National Institute on Aging (R01AG11378, P01AG010491, P50‐AG16574, U01AG06786, AG 024904, R01AG027342, U01AG006786, R01AG011378, P30AG019610, U19AG010483, P50AG016574)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, mild cognitive impairment, amyloid deposition, neurodegeneration, brain atrophy, ventriculomegaly, Pittsburgh compound B PET, serial imaging, amyloid plaques, cognitive decline, Alzheimer's Disease Neuroimaging Initiative, brain atrophy rate
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Aniline Compounds, Atrophy, Brain, Carbon Radioisotopes, Cognition Disorders, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Thiazoles, Time Factors, Case-Control Studies, Amyloid beta-Peptides, Statistics, Nonparametric, Radiopharmaceuticals, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.